Tobramycin Complexes for Enhanced Corneal Permeation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current tobramycin ophthalmic products face limitations in drug availability and bioavailability due to low corneal permeability and retention, requiring frequent dosing and posing risks of side effects such as increased intraocular pressure and glaucoma, with no approved products adequately addressing these issues in nearly four decades.
Innovation Solution
Development of tobramycin compound complexes or derivatives that are modified to enhance corneal permeation and retention, using complexing agents like histidine or PCL-PVAc-PEG, allowing for reduced dosing frequencies and extended release, thereby improving therapeutic efficacy and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If higher concentrations of tobramycin are used to improve therapeutic efficacy, then antimicrobial effectiveness increases, but ocular irritation and side effects increase
Solution Approach 1:
The patent uses complexing agents (histidine, PCL-PVAc-PEG) as intermediaries to bind tobramycin, creating a delivery system that controls drug release. This mediator approach allows higher tobramycin concentrations to be delivered without directly irritating the ocular surface, as the complexing agent modulates the interaction between the drug and ocular tissues.
Solution Approach 2:
The patent modifies the chemical parameters of tobramycin by forming complexes with different agents, changing its physical-chemical properties such as solubility, stability, and ocular penetration. These parameter changes enable higher effective concentrations to reach the cornea while maintaining acceptable safety profiles through controlled release mechanisms.
2Object-affected harmful factors
If conventional tobramycin formulations are used with low corneal permeability, then ocular safety is maintained, but dosing frequency must be increased
Solution Approach 1:
The patent implements continuous drug delivery through complex formulations that provide sustained release of tobramycin from the cornea. The complexing agents and formulation systems maintain therapeutic concentrations over extended periods, ensuring continuous antimicrobial action without requiring frequent re-dosing, thereby reducing the total number of administrations needed.
Solution Approach 2:
The patent uses excessive action by delivering higher initial concentrations of tobramycin through the complex formulation, which then provides prolonged retention and slow release from the cornea. This approach ensures sufficient drug levels are maintained throughout the dosing interval, preventing the need for frequent supplementation doses.
3Object-affected harmful factors
If tobramycin is delivered at approved concentrations with low corneal retention, then ocular tolerance is maintained, but therapeutic coverage is insufficient
Solution Approach 1:
The patent creates composite material systems by combining tobramycin with complexing agents (histidine, PCL-PVAc-PEG) and other formulation components. These composite formulations enhance corneal retention through multiple mechanisms including binding interactions, controlled release properties, and improved corneal penetration, thereby extending the duration of therapeutic action while maintaining ocular tolerance.
Solution Approach 2:
The patent employs a nested structure where tobramycin molecules are embedded within complexing agent structures, which are further incorporated into formulation systems. This nested arrangement protects the drug, controls its release kinetics, and enhances its retention in the cornea, extending therapeutic duration without increasing acute toxicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified tobramycin formulations demonstrate significantly increased corneal penetration and retention, reducing dosing frequency, enhancing therapeutic outcomes, and minimizing side effects, with improved patient compliance and efficacy compared to conventional products.
Implementation Method 1
tobramycin compound complexes or derivatives that are modified to enhance corneal permeation and retention, using complexing agents like histidine or PCL-PVAc-PEG
Data Source
AI summary
Disclosed herein are methods of treating conditions of the eye comprising delivering an effective amount of a composition comprising tobramycin or a tobramycin derivative exhibiting similar properties complexed to an agent which facilitates improved permeation of corneal cells, retention in corneal cells, or both. In aspects, such compositions further comprise, or such methods further comprise associated administration of (e.g., as a combined product or via co-administration), one or more additional active agents capable of supporting the treatment of the indication for which the compounds of the invention are directed, such as additional antibacterial compounds, anti-inflammatory agents (e.g., steroids), and the like.